OneOme Collaborates on Nation's Largest Population-Based Pharmacogenomics Study

MINNEAPOLIS (May 31, 2017) – Pharmacogenomic company OneOme announced today it is working with leading health institutions on the nation’s largest population-based pharmacogenomics study.

Pharmacogenomics is an emerging field that combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics). The study, developed and led by Mayo Clinic, is called the RIGHT 10K study and its purpose is to examine the health and economic outcomes of pharmacogenomics in 10,000 participants. The study will use the laboratory services at Baylor to sequence genomic data from participants recruited from the Mayo Clinic Biobank, along with OneOme’s services to interpret and deliver each participant’s pharmacogenomics data to clinicians in an understandable, electronic format.

“OneOme is excited to participate in the RIGHT 10K study with two of the nation’s leading health institutions – Mayo Clinic and Baylor,” Jason Ross, Chief Technical Officer of OneOme, said. “Mayo Clinic’s foresight in bringing us together to advance the future of precision medicine reflects the power of collaboration in advancing medicine.”

The RIGHT 10K study will gauge the effectiveness of pharmacogenomics data for the 10,000 participants. This includes embedding pharmacogenomics data into each patient’s electronic medical record pre-emptively – meaning before that patient knows he/she needs it. Mayo Clinic then will evaluate whether access to that genetic information improves long-term health and economic outcomes for patients and the overall health system.

The study will address one of the barriers to widespread adoption of pharmacogenomics testing – lack of studies on its long-term effectiveness. While the benefits are well understood for patients facing drug-drug interactions, adverse reactions and other specific medical conditions, benefit of pre-emptive testing for the general population are not yet well studied or documented.

More than four billion prescriptions are issued each year in the U.S., however, not all drugs are effective for all people. In fact, response rates for many drugs are only between 50-75 percent. Adverse drug reactions are now the fourth-leading cause of death. Pharmacogenomics can help reduce this statistic.

A previous Mayo Clinic study found that 99 percent of 1013 participants have a clinically actionable gene that affects their drug response. OneOme’s RightMed test, which was co-developed and exclusively licensed from Mayo Clinic, makes prescriptions personal by using a patient’s genetic information to better predict their response to medication.

OneOme provides a powerful suite of products including the RightMed pharmacogenomic test, RightMed pharmacogenomic interpretation report, and clinical decision tools that allow the company to interpret pharmacogenomics data from various sources and provide guidance using its knowledge base. Participants in the 10K study will receive the OneOme RightMed pharmacogenomic interpretation report, and the results will be integrated into their electronic medical record (EMR).

For providers and patients not participating in the RIGHT 10K, the RightMed pharmacogenomic test covers 22 genes, allows clinicians to make decisions across more than 340 medications for more than 20 medical indications, and can be integrated into their EMR. For providers and pharmacists, the RightMed test also includes the RightMed Advisor, an online, interactive tool for accessing OneOme’s expertly curated pharmacogenomic database. The tool provides insight into the pharmacologic impact of genomic variants and drug-drug interactions, a summary of pharmacogenomic clinical guidelines, and curated lists of alternative medications.

About OneOme
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit